Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare Form Of Gastric Cancer
Portfolio Pulse from Vandana Singh
Merck announced positive topline data from the Phase 3 KEYNOTE-811 trial of Keytruda plus trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The study met one of its dual primary endpoints of progression-free survival (PFS). Merck is working with the FDA to update the current indication for Keytruda in HER2-positive gastric or GEJ adenocarcinoma to those patients whose tumors are PD-L1 positive.
June 16, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda combo therapy showed positive results in a Phase 3 trial for HER2-positive advanced gastric cancer, potentially leading to an updated FDA indication.
The positive results from the Phase 3 KEYNOTE-811 trial indicate that Keytruda, in combination with trastuzumab and chemotherapy, demonstrated a statistically significant improvement in progression-free survival compared to placebo. This may lead to an updated FDA indication for Keytruda in HER2-positive gastric or GEJ adenocarcinoma, which could potentially increase the market for the drug and have a positive impact on Merck's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100